Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | PDE9A | O76083 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6530428 | 0.82 | ADORA2B (0.40) | TYMPADORA2AADORA2B | |
| SCHEMBL6531278 | 0.78 | CYP3A4 (0.32) | TYMP | |
| SCHEMBL6530225 | 0.77 | PDE4D (0.33) | TYMP | |
| SCHEMBL9116775 | 0.77 | KDM4E (0.42) | KDM4ETYMPTAAR1PDE9AHPGD | |
| SCHEMBL30396329 | 0.76 | TYMP (0.51) | KDM4ETYMPTAAR1PDE9AHPGD | |
| SCHEMBL21750418 | 0.75 | TYMP (0.52) | KDM4ETYMPHPGDTAS1R3TAS1R1 | |
| SCHEMBL22577545 | 0.75 | TYMP (0.52) | KDM4ETYMPHPGDTAS1R3TAS1R1 | |
| SCHEMBL20773183 | 0.75 | TYMP (0.43) | KDM4ETYMPTAAR1PDE9AHPGD | |
| SCHEMBL30679321 | 0.74 | TYMP (0.57) | KDM4ETYMPTAS1R3TAS1R1 | |
| SCHEMBL18490308 | 0.74 | TYMP (0.60) | KDM4ETYMPTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050266422-A1 | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides | SIRNA THERAPEUTICS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266422-A1 | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides | NSUN3, IRF3, SNRPF | KDM4E 4548/4885TYMP 598/4885TAAR1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.